



## Haemonetics 2nd Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website

November 7, 2022

*Financial release accessible online*

BOSTON, Nov. 7, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal 2023, which ended October 1, 2022, are available on its Investor Relations website.



The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on November 7, 2022. The conference call and webcast can be accessed with the following information:

- Teleconference link: <https://register.vevent.com/register/BI40288651d4b2472199bac5fd76e59174>
- Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
- A live webcast of the call can be accessed on Haemonetics' investor relations website or via the following link: <https://edge.media-server.com/mmc/p/jmqoyvd8>

In addition, the Company has posted to its Investor Relations website the earnings release and analytical tables and supplemental information that will be referenced on its conference call and webcast, direct links to which are available below.

Direct link to 2Q FY23 Earnings Release:

<https://haemonetics.gcs-web.com/static-files/f7bd49f3-53f3-412d-9e2f-a8793baa052b>

Direct link to 2Q FY23 Analytical Tables and Supplemental Information:

<https://haemonetics.gcs-web.com/static-files/f02bd23c-d80b-491e-ab3a-f299118c93f3>

A replay of the conference call and webcast will be available for one year beginning on November 7, 2022, at 11:00 a.m. ET using the conference call webcast link provided in this press release.

### About Haemonetics

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit [www.haemonetics.com](http://www.haemonetics.com).

### Investor Contacts:

Olga Guyette, Sr. Director-Investor Relations & Treasury David Trenk, Manager-Investor Relations  
(781) 356-9763 203) 733-4987  
[olga.guyette@haemonetics.com](mailto:olga.guyette@haemonetics.com) [david.trenk@haemonetics.com](mailto:david.trenk@haemonetics.com)

### Media Contact:

Josh Gitelson, Director-Global Communications  
(781) 356-9776  
[josh.gitelson@haemonetics.com](mailto:josh.gitelson@haemonetics.com)

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/haemonetics-2nd-quarter-fiscal-year-2023-earnings-release-available-on-investor-relations-website-301669873.html>

SOURCE Haemonetics Corporation